Despite attempts to solve problems with shortages of brand-name medicines in the UK, the issue is far from beings resolved. The latest news is that the UK’s wholesalers have called for a ‘third-party monitoring and survey service’ to help tackle medicines shortages, while the Association of the British Pharmaceutical Industry (ABPI) is calling for sanctions on pharmacists that act as wholesalers.
Drug shortage woes continue in the UK
Home/Pharma News
|
Posted 27/01/2012
0
Post your comment

The British Association of Pharmaceutical Wholesalers (BAPW) has called on pharmacists and manufacturers to support objective monitoring and reporting of brand-name medicine supplies. The association stressed that the introduction of a third-party monitoring and survey service of medicine supplies to pharmacies and dispensing doctors needed ‘urgent consideration’.
The BAPW adds that although the various stakeholders are working together more closely, ‘inefficiencies remain in the supply chain’, which the BAPW feels could be rebalanced by ‘regulatory enforcement’ and ‘adjustment’.
Meanwhile, the ABPI are calling for the legal separation of pharmacies’ wholesaling and dispensing activities to ensure patients ‘get priority’ when medicines are in short supply according to Chemist+Druggist. The ABPI believe that separating the activities would ensure pharmacists put patients before business.
Currently in the UK there are 1,800 wholesaler licences, which enable pharmacists to export medicines for profit, possibly exacerbating drug shortages. The UK medicines authority–Medicines and Healthcare products Regulatory Agency–has already stated that pharmacists with ‘unusual purchasing patterns’ could face investigation over their exporting businesses.
The views of the APBI and BAPW are expected to be presented at the first oral evidence session of the All-Party Pharmacy Group’s (APPG’s) Inquiry into medicine shortages, which was scheduled at the House of Commons on 24 January 2012.
Related articles
UK drug shortages are far from being solved
UK drug shortages continue to affect pharmacists and patients
Source: BAPW, Chemist+Druggist
Guidelines
FDA issues guidance on AI use in drug and biologicals regulatory decision making
ICH adopts Good Clinical Practice Guideline for clinical trials
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA
Biosimilars thrive as China’s biotech industry gains momentum
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations
Bio-Thera partners with Tabuk in Saudi Arabia and SteinCares in LATAM

Home/Pharma News Posted 18/02/2025
Klinge-Teva and MS Pharma agreements for Eylea and Stelara biosimilars in Europe and MENA

Home/Pharma News Posted 06/02/2025
Greener Pharmaceuticals: WHO's call for innovative regulatory practices and eco-friendly innovations

Home/Pharma News Posted 15/01/2025
The best selling biotechnology drugs of 2008: the next biosimilars targets

Post your comment